You mentioned a set of tests in the previous post. How do we interpret those test results
...and apply it to immunochemo?
Assuming we do 5FU+VitC (and Avastin every 3 weeks)
what would need to be changed when one of the test results fall outside the expected range?
Effects of daily oral administration of quercetin chalcone and modified
citrus pectin on implanted colon-25 tumor growth in Balb-c mice.
The health benefits of fruits and vegetables have been the subject of
numerous investigations over many years. Two natural substances, quercetin
(a flavonoid) and citrus pectin (a polysaccharide found in the cell wall of
plants) are of particular interest to cancer researchers. Two modified
versions of these substances - quercetin chalcone (QC) and a pH-modified
citrus pectin (MCP) - are the focus of this study. Previous research has
confirmed that quercetin exhibits antitumor properties, likely due to immune
stimulation, free radical scavenging, alteration of the mitotic cycle in
tumor cells, gene expression modification, anti-angiogenesis activity, or
apoptosis induction, or a combination of these effects. MCP has inhibited
metastases in animal studies of prostate cancer and melanoma. To date, no
study has demonstrated a reduction in solid tumor growth with MCP, and there
is no research into the antitumor effect of QC. This study examines the
effects of MCP and QC on the size and weight of colon-25 tumors implanted in
balb-c mice. Fifty mice were orally administered either 1 ml distilled water
(controls), low-dose QC (0.8 mg/ml), high-dose QC (1.6 mg/ml), low-dose MCP
(0. 8 mg/ml) or high-dose MCP (1.6 mg/ml) on a daily basis, beginning the
first day of tumor palpation (usually eight days post-implantation). A
significant reduction in tumor size was noted at day 20 in all groups
compared to controls. The groups given low-dose QC and MCP had a 29% (NS)
and 38% (p<0.02) decrease in size, respectively. The high-dose groups had an
even more impressive reduction in size; 65% in the QC group and 70% in the
mice given MCP (both p<0.001). This is the first evidence that MCP can
reduce the growth of solid primary tumors, and the first research showing QC
has antitumor activity. Additional research on these substances and their
effect on human cancers is warranted.
Altern Med Rev. 2000 Dec;5(6):546-52
Inhibitory effect of modified citrus pectin on liver metastases in a mouse
colon cancer model.
AIM: To discuss the expression of glactin-3 in liver metastasis of colon
cancer and its inhibition by modified citrus pectin (MCP) in mice. METHODS:
Seventy-five Balb/c mice were randomly divided into negative control group
(n = 15), positive control group (n = 15), low MCP concentration group (n =
15), middle MCP concentration group (n = 15) and high MCP concentration
group (n = 15). CT26 colon cancer cells were injected into the subcapsule of
mouse spleen in positive control group, low, middle and high MCP
concentrations groups, except in negative control, to set up a colon cancer
liver metastasis model. The concentration of MCP in drinking water was 0.0%,
0.0%, 1.0%, 2.5% and 5.0% (wt/vol), respectively. Liver metastasis of colon
cancer was observed after 3 wk. Enzyme-linked immunosorbent assay (ELISA)
was used to detect the concentration of galectin-3 in serum. Expression of
galectin-3 in liver metastasis was detected by immunohistochemistry.
RESULTS: Except for the negative group, the percentage of liver metastasis
in the other 4 groups was 100%, 80%, 73.3% and 60%, respectively. The number
of liver metastases in high MCP concentration group was significantly less
than that in positive control group (P = 0.008). Except for the negative
group, the median volume of implanted spleen tumor in the other 4 groups was
1.51 cm(3), 0.93 cm(3), 0.77 cm(3) and 0.70 cm(3), respectively. The volume
of implanted tumor in middle and high MCP concentration groups was
significantly smaller than that in positive control group (P = 0.019; P =
0.003). The concentration of serum galectin-3 in positive control and MCP
treatment groups was significantly higher than that in the negative control
group. However, there was no significant difference between them. Except for
the negative control group, the expression of galectin-3 in liver metastases
of the other 4 groups showed no significant difference. CONCLUSION:
Expression of galetin-3 increases significantly in liver metastasis of colon
cancer, which can be effectively inhibited by MCP.
World J Gastroenterol. 2008 Dec 28;14(48):7386-91
Expression of galectin-3 in liver metastasis of colon cancer and the
inhibitory effect of modified citrus pectin.
OBJECTIVE: To observe the expression of galectin-3 in the liver metastasis
of colon cancer in mice and the inhibitory effect of modified citrus pectin
(MCP) on galectin-3 expression. METHODS: Seventy-five Balb/c mice were
randomized into 5 groups, namely the negative control, positive control,
low-concentration MCP, moderate-concentration MCP and high-concentration MCP
groups. CT26 colon cancer cells were injected into the subcapsule of the
mouse spleen to establish liver metastasis models of colon cancer, but the
mice in the negative control group received no tumor cell injection. MCP was
added into the drinking water of the mice at the concentrations of 0, 1.0%,
2.5% and 5.0% (m/V). The liver metastasis was observed 3 weeks after tumor
cell inoculation. Enzyme-linked immunosorbent assay was performed to
determine the serum galectin-3 level. A tissue microarray of the liver
metastasis was prepared for immunohistochemical detection of galectin-3
expression in the liver metastasis. RESULTS: In the positive control, low-,
moderate- and high-concentration MCP groups, the rates of liver metastasis
were 100%, 80%, 73.3% and 60%, respectively. The number of liver metastases
in high-concentration MCP group was significantly smaller than that in the
positive control group (P<0.05). In the 4 groups with tumor cell
inoculation, the median volume of the primary lesions in the spleen was
1.51, 0.93, 0.77 and 0.70 cm(3), respectively, which were significantly
smaller in the moderate- and high-concentration MCP groups than in the
positive control group (P<0.05). The serum galectin-3 level in the positive
control group and MCP-treated groups were significantly higher than that in
the negative control group (P<0.01), but similar between the positive
control group and the MCP-treated groups (P>0.05). In the positive control
and the MCP-treated groups, the expression of galectin-3 in the liver
metastases showed no significant differences (P>0.05). CONCLUSION: The
expression of galetin-3 is significantly increased in the liver metastasis
of colon cancer, and MCP can effectively inhibit the liver metastasis.
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(8):1358-6
Rp, what do u look for in the CA19-9??? In relation to the
cimetidine?,
I think im no MSS, and kras braf neg as thats what my original biopsy at colonoscopy
sugestes on the he lab report that ive got a hold of but they keep saying tumor has to b removed to test??? ( conflicting) My question is am I only waisting my time with all this if im not kras positive??? Apart from the VIT C??
My surgon refers to tumors like birds Some can fly ( metastasize) Some can't ( in situ)
But won't know until its fully removed during surgery and tested along with lymphs!!!!
But when I mentioned lymph node invasion he pretty much said they may never b able to tell If they had cancer in them if they were destroyed by the radiation or weather they were just enlarged, doing their job( fighting off the cancerous tumor)
Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”
Users browsing this forum: Google [Bot] and 164 guests